Pediatric Atypical Teratoid/Rhabdoid Tumors of the Brain: Identification of Metabolic Subgroups Using In Vivo ¹H-MR Spectroscopy

REFERENCES

1. 1.↵
   2. Ostrom QT,
   3. Gittleman H,
   4. Fulop J, et al

   . CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro Oncol 2015;17(Suppl 4):iv1–62 doi:10.1093/neuonc/nov189 pmid:26511214

   CrossRefPubMed
2. 2.↵
   1. Ries L,
   2. Smith M,
   3. Gurney J, et al

   2. Gurney J,
   3. Smith M,
   4. Bunin G

   . CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries L, Smith M, Gurney J, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995. Bethesda: National Cancer Institute, SEER Program. NIH Pub. No. 99–4649; 1999
3. 3.↵
   2. Biegel JA,
   3. Zhou JY,
   4. Rorke LB, et al

   . Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999;59:74–79 pmid:9892189

   Abstract/FREE Full Text
4. 4.↵
   2. Versteege I,
   3. Sévenet N,
   4. Lange J, et al

   . Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998;394:203–06 doi:10.1038/28212 pmid:9671307

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Richardson EA,
   3. Ho B,
   4. Huang A

   . Atypical teratoid rhabdoid tumour: from tumours to therapies. J Korean Neurosurg Soc 2018;61:302–11 doi:10.3340/jkns.2018.0061 pmid:29742888

   CrossRefPubMed
6. 6.↵
   2. Ginn KF,
   3. Gajjar A

   . Atypical teratoid rhabdoid tumor: current therapy and future directions. Front Oncol 2012;2:114 doi:10.3389/fonc.2012.00114 pmid:22988546

   CrossRefPubMed
7. 7.↵
   2. Torchia J,
   3. Golbourn B,
   4. Feng S, et al

   . Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. Cancer Cell 2016;30:891–908 doi:10.1016/j.ccell.2016.11.003 pmid:27960086

   CrossRefPubMed
8. 8.↵
   2. Johann PD,
   3. Erkek S,
   4. Zapatka M, et al

   . Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 2016;29:379–93 doi:10.1016/j.ccell.2016.02.001 pmid:26923874

   CrossRefPubMed
9. 9.↵
   2. Nowak J,
   3. Nemes K,
   4. Hohm A, et al

   . Magnetic resonance imaging surrogates of molecular subgroups in atypical teratoid/rhabdoid tumor. Neuro Oncol 2018;20:1672–79 doi:10.1093/neuonc/noy111 pmid:30010851

   CrossRefPubMed
10. 10.↵
    2. Torchia J,
    3. Picard D,
    4. Lafay-Cousin L, et al

    . Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol 2015;16:569–82 doi:10.1016/S1470-2045(15)70114-2 pmid:25882982

    CrossRefPubMed
11. 11.↵
    2. Eaton KW,
    3. Tooke LS,
    4. Wainwright LM, et al

    . Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer 2011;56:7–15 doi:10.1002/pbc.22831 pmid:21108436

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Panwalkar P,
    3. Clark J,
    4. Ramaswamy V, et al

    . Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol 2017;134:705–14 doi:10.1007/s00401-017-1752-4 pmid:28733933

    CrossRefPubMed
13. 13.↵
    2. Venneti S,
    3. Le P,
    4. Martinez D, et al

    . Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins. Am J Surg Pathol 2011;35:1463–72 doi:10.1097/PAS.0b013e318224d2cd pmid:21921784

    CrossRefPubMed
14. 14.↵
    2. Eaton BT,
    3. Hyatt AD,
    4. Brookes SM

    . The replication of bluetongue virus. Curr Top Microbiol Immunol 1990;162:89–118 pmid:2166649

    PubMedWeb of Science
15. 15.↵
    2. Venneti S,
    3. Garimella MT,
    4. Sullivan LM, et al

    . Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol 2013;23:558–64 doi:10.1111/bpa.12042 pmid:23414300

    CrossRefPubMed
16. 16.↵
    FDA. Multiple Endpoints in Clinical Trials. 2017. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf. Accessed September 18, 2018.
17. 17.↵
    2. Hanna-El-Daher L,
    3. Braissant O

    . Creatine synthesis and exchanges between brain cells: what can be learned from human creatine deficiencies and various experimental models? Amino Acids 2016;48:1877–95 doi:10.1007/s00726-016-2189-0 pmid:26861125

    CrossRefPubMed
18. 18.↵
    2. Braissant O,
    3. Henry H,
    4. Villard AM, et al

    . Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMT and CT1. BMC Dev Biol 2005;5:9 doi:10.1186/1471-213X-5-9 pmid:15918910

    CrossRefPubMed
19. 19.↵
    2. Fisher SK,
    3. Novak JE,
    4. Agranoff BW

    . Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J Neurochem 2002;82:736–54 doi:10.1046/j.1471-4159.2002.01041.x pmid:12358779

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Isaacks RE,
    3. Bender AS,
    4. Kim CY, et al

    . Osmotic regulation of myo-inositol uptake in primary astrocyte cultures. Neurochem Res 1994;19:331–38 doi:10.1007/BF00971582 pmid:8177373

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Brand A,
    3. Richter-Landsberg C,
    4. Leibfritz D

    . Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289–98 doi:10.1159/000111347 pmid:7805581

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Castillo M,
    3. Smith JK,
    4. Kwock L

    . Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000;21:1645–49 pmid:11039343

    Abstract/FREE Full Text
23. 23.↵
    2. Panigrahy A,
    3. Krieger MD,
    4. Gonzalez-Gomez I, et al

    . Quantitative short echo time 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. AJNR Am J Neuroradiol 2006;27:560–72 pmid:16551993

    Abstract/FREE Full Text
24. 24.↵
    2. Negendank W,
    3. Sauter R

    . Intratumoral lipids in 1H MRS in vivo in brain tumors: experience of the Siemens cooperative clinical trial. Anticancer Res 1996;16:1533–38 pmid:8694522

    PubMedWeb of Science
25. 25.↵
    2. Kuesel AC,
    3. Sutherland GR,
    4. Halliday W, et al

    . 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994;7:149–55 doi:10.1002/nbm.1940070308 pmid:8080717

    CrossRefPubMed
26. 26.↵
    2. Rock JP,
    3. Hearshen D,
    4. Scarpace L, et al

    . Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002;51:912–19, discussion 919–20 pmid:12234397

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Kuesel AC,
    3. Donnelly SM,
    4. Halliday W, et al

    . Mobile lipids and metabolic heterogeneity of brain tumours as detectable by ex vivo 1H MR spectroscopy. NMR Biomed 1994;7:172–80 doi:10.1002/nbm.1940070404 pmid:7946995

    CrossRefPubMed
28. 28.↵
    2. Jain M,
    3. Nilsson R,
    4. Sharma S, et al

    . Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012;336:1040–44 doi:10.1126/science.1218595 pmid:22628656

    Abstract/FREE Full Text